XNCR - Xencor GAAP EPS of -$0.57 misses by $0.10 revenue of $30.18M misses by $3.83M
- Xencor press release ( NASDAQ: XNCR ): Q2 GAAP EPS of -$0.57 misses by $0.10 .
- Revenue of $30.18M (-55.3% Y/Y) misses by $3.83M .
- “Later this year, we plan to present additional clinical data from our vudalimab and plamotamab programs and initial data from our IL2-Fc autoimmune program, XmAb564, in healthy volunteers. Near year-end we also expect to dose the first patient in the Phase 1 study of XmAb808, our B7-H3 x CD28 bispecific antibody, placing Xencor at the forefront of efforts to engage CD28 to selectively activate T cells.”
For further details see:
Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M